{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:07:48Z","timestamp":1791068868021,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/leu.2017.41","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T02:42:06Z","timestamp":1485312126000},"page":"2181-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":268,"title":["Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL"],"prefix":"10.1038","volume":"31","author":[{"given":"J","family":"Duell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Eisele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Dandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"BFleu201741_CR1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"SM Richards","year":"2007","unstructured":"Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 2007; 109: 944\u2013950.","journal-title":"Blood"},{"key":"BFleu201741_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120: 2032\u20132041.","journal-title":"Blood"},{"key":"BFleu201741_CR3","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1002\/cncr.25354","volume":"116","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010; 116: 5568\u20135574.","journal-title":"Cancer"},{"key":"BFleu201741_CR4","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O'Brien","year":"2008","unstructured":"O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113: 3186\u20133191.","journal-title":"Cancer"},{"key":"BFleu201741_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, Tormo M, Heras I, Rivas C et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010; 95: 589\u2013596.","journal-title":"Haematologica"},{"key":"BFleu201741_CR6","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","volume":"21","author":"E Tavernier","year":"2007","unstructured":"Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907\u20131914.","journal-title":"Leukemia"},{"key":"BFleu201741_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507\u20131517.","journal-title":"N Engl J Med."},{"key":"BFleu201741_CR8","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.","journal-title":"Sci Transl Med"},{"key":"BFleu201741_CR9","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817\u20134828.","journal-title":"Blood"},{"key":"BFleu201741_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517\u2013528.","journal-title":"Lancet"},{"key":"BFleu201741_CR11","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134\u20134140.","journal-title":"J Clin Oncol"},{"key":"BFleu201741_CR12","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier G, G\u00f6kbuget N, Klinger M, Viardot A, Stelljes M, Neumann S et al. Long-term survival and T-Cell kinetics in adult patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia who achieved minimal residual disease response following treatment with Anti-CD19 BiTE\u00ae antibody construct blinatumomab. Blood 2015; 126: 2578\u20132584.","journal-title":"Blood"},{"key":"BFleu201741_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57\u201366.","journal-title":"Lancet Oncol"},{"key":"BFleu201741_CR14","unstructured":"Topp MS, Stein A et al. Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lmyphoblastic leukemia in a randomized open label phase 3 study (Tower). EHA 2016; abstract S149."},{"key":"BFleu201741_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","volume":"13","author":"M Miyara","year":"2007","unstructured":"Miyara M, Sakaguchi S . Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007; 13: 108\u2013116.","journal-title":"Trends Mol Med."},{"key":"BFleu201741_CR16","doi-asserted-by":"crossref","unstructured":"Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A . CD4+ CD25+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166: 3008\u20133018.","DOI":"10.4049\/jimmunol.166.5.3008"},{"key":"BFleu201741_CR17","doi-asserted-by":"crossref","unstructured":"Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H et al. TGF-\u03b2 1 plays an important role in the mechanism of CD4+ CD25+ regulatory T cell activity in both humans and mice. J Immunol 172: 834\u2013842.","DOI":"10.4049\/jimmunol.172.2.834"},{"key":"BFleu201741_CR18","doi-asserted-by":"crossref","unstructured":"Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ . Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589\u2013601.","DOI":"10.1016\/j.immuni.2004.09.002"},{"key":"BFleu201741_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695\u20131710.","journal-title":"J Exp Med"},{"key":"BFleu201741_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/eji.201141651","volume":"42","author":"AN McMurchy","year":"2012","unstructured":"McMurchy AN, Megan KL . Suppression assays with human T regulatory cells: a technical guide. Eur J Immunol 2012; 42: 27\u201334.","journal-title":"Eur J Immunol"},{"key":"BFleu201741_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2307\/2342435","volume":"98","author":"RA Fisher","year":"1935","unstructured":"Fisher RA . The logic of inductive inference. J R Stat Soc Ser A 1935; 98: 39\u201354.","journal-title":"J R Stat Soc Ser A"},{"key":"BFleu201741_CR22","unstructured":"Breiman L, Friedman JH, Olshen RA, Stone CJ Classification and Regression Trees. Wadsworth: Belmont, CA, USA."},{"key":"BFleu201741_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000048247","volume":"62","author":"M Nowicki","year":"2002","unstructured":"Nowicki M, Mi\u015bkowiak B, Kaczmarek-Kanold M . Correlation between early treatment failure and Ki67 antigen expression in blast cells of children with acute lymphoblastic leukaemia before commencing treatment. A retrospective study. Oncology 2002; 62: 55\u201359.","journal-title":"Oncology"},{"key":"BFleu201741_CR24","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"6","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 6 120: 2032\u20132041.","journal-title":"Blood"},{"key":"BFleu201741_CR25","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226\u20136233.","journal-title":"Blood"},{"key":"BFleu201741_CR26","first-page":"159","volume":"103","author":"H Niewiadomska","year":"2000","unstructured":"Niewiadomska H, Mirowski M, Kulczycka D, Najder M, Balcerczak E, B\u0142o\u0144ski JZ . Some oncogene and tumour suppressor gene protein products expression in B-cell chronic lymphocytic leukaemia. Cytobios 2000; 103: 159\u2013168.","journal-title":"Cytobios"},{"key":"BFleu201741_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ . How regulatory T cells work. Nat Rev Immunol 2008; 8: 523\u2013532.","journal-title":"Nat Rev Immunol"},{"key":"BFleu201741_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S et al. IL-10 elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell 2011; 20: 781\u2013796.","journal-title":"Cancer Cell"},{"key":"BFleu201741_CR29","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.4049\/jimmunol.1101760","volume":"188","author":"S Koristka","year":"2012","unstructured":"Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188: 1551\u20131558.","journal-title":"J Immunol"},{"key":"BFleu201741_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635\u2013646.","journal-title":"Immunity"},{"key":"BFleu201741_CR31","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA . CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015; 125: 4017\u20134023.","journal-title":"Blood"},{"key":"BFleu201741_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","volume":"42","author":"MT Madondo","year":"2016","unstructured":"Madondo MT, Quinn M, Plebanski M . Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev 2016; 42: 3\u20139.","journal-title":"Cancer Treat Rev"},{"key":"BFleu201741_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641\u2013648.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu201741_CR34","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","volume":"106","author":"M Beyer","year":"2005","unstructured":"Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018\u20132025.","journal-title":"Blood"},{"key":"BFleu201741_CR35","first-page":"2728","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic. leukemia 2013; 119: 2728\u20132736.","journal-title":"leukemia"},{"key":"BFleu201741_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134\u2013144.","journal-title":"N Engl J Med"},{"key":"BFleu201741_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415\u2013421.","journal-title":"Nature"},{"key":"BFleu201741_CR38","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627\u20131639.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201741","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu201741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:11:21Z","timestamp":1684419081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFleu201741"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.41","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]},"assertion":[{"value":"27 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MST is an advisory board member, an honorary speaker and a travel support at Amgen. JD, TB, TM, MD, TD, HE, FE, FE, EH and AR declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}